Garuda Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
09 Jan 2024
Cell Therapy
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Garuda Therapeutics (Garuda), a company creating off-the-shelf, blood stem cell therapies, today announced that Dhvanit Shah, Ph.D., Co-founder, President and Chief Executive Officer, will present a company overview at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10 at 9:30 am PT.
Garuda’s breakthrough platform and manufacturing technology for making Hematopoietic Stem Cells (gHSCs) offers the potential to provide curative, off-the-shelf treatments for patients around the world.
About Garuda Therapeutics
Garuda Therapeutics seeks to create a world that eliminates the dependency on donor or patient cells for blood stem cell transplants. Our platform technology for generating off-the-shelf, self-renewing blood stem cells is poised to provide patients with rapid and broad access to consistent, durable, HLA-compatible and transgene-free blood stem cell therapies. Like bone marrow transplants, our technology could provide potentially curative therapies for more than 120 diseases. https://garudatx.com/
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.